Alembic Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹825.10
Market cap
16,129 Cr
Stock P/E
24.8
P/B
2.85
Dividend yield
1.3%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,486 Cr | 1,595 Cr | 1,631 Cr | 1,517 Cr | 1,562 Cr | 1,648 Cr | 1,693 Cr | 1,770 Cr | 1,711 Cr | 1,910 Cr | 1,876 Cr | 1,848 Cr |
| Operating expenses (approx.) | 1,276 Cr | 1,377 Cr | 1,361 Cr | 1,253 Cr | 1,323 Cr | 1,379 Cr | 1,423 Cr | 1,484 Cr | 1,423 Cr | 1,588 Cr | 1,610 Cr | 1,619 Cr |
| EBITDA | 210 Cr | 218 Cr | 269 Cr | 264 Cr | 239 Cr | 269 Cr | 270 Cr | 286 Cr | 288 Cr | 323 Cr | 267 Cr | 229 Cr |
| OPM % | 14.2% | 13.7% | 16.5% | 17.4% | 15.3% | 16.3% | 15.9% | 16.2% | 16.8% | 16.9% | 14.2% | 12.4% |
| Other income | 12 Cr | 10 Cr | 3 Cr | 4 Cr | 2 Cr | 17 Cr | 10 Cr | 14 Cr | 7 Cr | 7 Cr | 16 Cr | 26 Cr |
| Interest | 14 Cr | 16 Cr | 15 Cr | 11 Cr | 13 Cr | 19 Cr | 22 Cr | 25 Cr | 24 Cr | 24 Cr | 23 Cr | 23 Cr |
| Depreciation | 66 Cr | 68 Cr | 69 Cr | 69 Cr | 69 Cr | 71 Cr | 70 Cr | 69 Cr | 74 Cr | 76 Cr | 80 Cr | 89 Cr |
| Profit before tax | 130 Cr | 135 Cr | 185 Cr | 183 Cr | 157 Cr | 180 Cr | 177 Cr | 193 Cr | 191 Cr | 222 Cr | 163 Cr | 118 Cr |
| Tax % | 7.1% | -1.4% | 2.2% | 2.5% | 14.4% | 15.2% | 22.6% | 18.3% | 19.1% | 18.0% | 18.1% | -70.5% |
| Net profit | 121 Cr | 137 Cr | 180 Cr | 178 Cr | 135 Cr | 153 Cr | 138 Cr | 157 Cr | 154 Cr | 184 Cr | 132 Cr | 202 Cr |
| EPS (₹) | ₹6.14 | ₹6.95 | ₹9.18 | ₹9.07 | ₹6.85 | ₹7.79 | ₹7.01 | ₹7.98 | ₹7.85 | ₹9.40 | ₹6.76 | ₹10.31 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,935 Cr | 4,606 Cr | 5,393 Cr | 5,306 Cr | 5,653 Cr | 6,229 Cr | 6,672 Cr | 7,345 Cr | Sign in for TTM |
| Operating expenses (approx.) | 3,052 Cr | 3,421 Cr | 3,826 Cr | 4,381 Cr | 4,944 Cr | 5,295 Cr | 5,651 Cr | 6,239 Cr | Sign in for TTM |
| EBITDA | 883 Cr | 1,184 Cr | 1,568 Cr | 925 Cr | 708 Cr | 933 Cr | 1,021 Cr | 1,106 Cr | Sign in for TTM |
| OPM % | 22.4% | 25.7% | 29.1% | 17.4% | 12.5% | 15.0% | 15.3% | 15.1% | Sign in for TTM |
| Other income | 9 Cr | 5 Cr | 10 Cr | 50 Cr | 3 Cr | 28 Cr | 43 Cr | 54 Cr | Sign in for TTM |
| Interest | 18 Cr | 27 Cr | 16 Cr | 18 Cr | 50 Cr | 56 Cr | 79 Cr | 94 Cr | Sign in for TTM |
| Depreciation | 115 Cr | 157 Cr | 183 Cr | 287 Cr | 275 Cr | 273 Cr | 279 Cr | 319 Cr | Sign in for TTM |
| Profit before tax | 749 Cr | 1,000 Cr | 1,368 Cr | 620 Cr | 386 Cr | 633 Cr | 706 Cr | 694 Cr | Sign in for TTM |
| Tax % | 20.9% | 19.9% | 18.5% | 16.8% | 3.3% | 2.5% | 17.7% | 3.3% | Sign in for TTM |
| Net profit | 583 Cr | 801 Cr | 1,147 Cr | 521 Cr | 342 Cr | 616 Cr | 582 Cr | 671 Cr | Sign in for TTM |
| EPS (₹) | ₹31.00 | ₹43.97 | ₹60.81 | ₹27.76 | ₹17.40 | ₹31.33 | ₹29.68 | ₹34.33 | Sign in for TTM |
| Dividend payout % | — | — | — | 52.8% | 57.5% | 25.5% | 37.2% | 32.2% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 38 Cr | 38 Cr | 39 Cr | 39 Cr | 39 Cr | 39 Cr | 39 Cr | 39 Cr |
| Reserves | 2,681 Cr | 3,182 Cr | 5,088 Cr | 5,198 Cr | 4,331 Cr | 4,779 Cr | 5,152 Cr | 5,636 Cr |
| Borrowings | — | — | — | — | 636 Cr | 430 Cr | 1,196 Cr | 1,361 Cr |
| Other liabilities | — | — | — | — | 1,176 Cr | 1,197 Cr | 1,388 Cr | 1,733 Cr |
| Total liabilities | — | — | — | — | 6,183 Cr | 6,446 Cr | 7,773 Cr | 8,763 Cr |
| Fixed assets (net) | — | — | — | — | 2,398 Cr | 2,547 Cr | 2,524 Cr | 2,844 Cr |
| CWIP | — | — | — | — | 601 Cr | 524 Cr | 837 Cr | 634 Cr |
| Investments | — | — | — | — | 71 Cr | 69 Cr | 101 Cr | 113 Cr |
| Other assets | — | — | — | — | 2,910 Cr | 3,079 Cr | 4,088 Cr | 4,543 Cr |
| Total assets | — | — | — | — | 6,183 Cr | 6,446 Cr | 7,773 Cr | 8,763 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 552 Cr | 724 Cr | 803 Cr | 88 Cr | 783 Cr |
| Cash from investing | — | — | — | -372 Cr | -448 Cr | -321 Cr | -568 Cr | -506 Cr |
| Cash from financing | — | — | — | -217 Cr | -262 Cr | -438 Cr | 444 Cr | -164 Cr |
| Net cash flow | — | — | — | -37 Cr | 14 Cr | 45 Cr | -37 Cr | 113 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 127 Cr | 281 Cr | 476 Cr | -476 Cr | 348 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 28.2% | 31.9% | 27.0% | 12.2% | 8.6% | 12.6% | 11.6% | 11.2% |
| ROE % | -0.0% | 25.7% | 23.0% | 10.4% | 7.8% | 12.8% | 11.2% | 11.8% |
| Debtor days | — | — | — | — | 67 | 60 | 76 | 73 |
| Inventory days | — | — | — | — | 430 | 428 | 498 | 523 |
| Days payable | — | — | — | — | 198 | 191 | 192 | 174 |
| Cash conversion cycle | — | — | — | — | 299 | 296 | 383 | 422 |
| Debt / equity | — | — | 0.00 | 0.00 | 0.15 | 0.09 | 0.23 | 0.24 |
| Current ratio | — | — | — | — | 1.78 | 2.12 | 1.69 | 1.75 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.79 | 0.33 | 1.09 | 1.05 |
Compare with peers
Loading peers…